F
Frontera Therapeutics
AAV gene therapy company that focuses on rAAV therapies for the global market
About Frontera Therapeutics
Frontera Therapeutics is a clinical-stage biotechnology company that focuses on the development of gene therapy medicines. Their mission is to improve the lives of patients across multiple disease areas. They operate in the biotechnology market, serving clients such as healthcare providers and patients suffering from various diseases.
Their business model revolves around their APEX Technology & Manufacturing Platform. This platform is an innovative adeno-associated virus (AAV) gene expression system. In simpler terms, it's a system that uses a type of virus to deliver genes into cells. This technology includes novel and clinically validated AAV vectors, efficient and fully-integrated CMC processes, and access to early clinical data. This allows Frontera to develop new gene therapy products faster and at a lower cost.
Frontera generates revenue by developing and selling these gene therapy products. Their product development spans across not only rare genetic disorders, but also larger patient markets, including Ophthalmology, Hematology, Cardiovascular, and Metabolic Diseases.
The company boasts a world-class R&D team, state-of-the-art GMP facilities, and a proven team in gene therapy R&D. They have early access to clinical data due to their unique scientific model, which gives them a competitive edge in the market.
In conclusion, Frontera Therapeutics is a pioneering biotech company that leverages innovative technology to develop gene therapy medicines, aiming to improve patient lives across a broad spectrum of diseases.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Pudong, China
- Employees
- 22
- Open positions
- None listed
- Dealroom signal
- 64.8/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jun 2022 | $160M | $640M | Creacion Ventures · HongShan · Sequoia · Boyu Capital | ↗ |
| SERIES AOther financing | Sep 2019 | $35M | $140M | OrbiMed · Creacion Ventures | ↗ |
Growth signals
Latest recorded traffic for Frontera Therapeutics is 1.4K monthly website visits, up 70.7% over the last three months. Frontera Therapeutics's team declined 12% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Frontera Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Frontera Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.











